Folgen
Benet lz
Benet lz
Bestätigte E-Mail-Adresse bei ucsf.edu
Titel
Zitiert von
Zitiert von
Jahr
Giving full measure to countermeasures: addressing problems in the DoD program to develop medical countermeasures against biological warfare agents
LZ Benet, JS Durch, LM Joellenbeck
National Academies Press, 2004
3827*2004
Membrane transporters in drug development
Nature reviews Drug discovery 9 (3), 215-236, 2010
34752010
Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system
CY Wu, LZ Benet
Pharmaceutical research 22, 11-23, 2005
16862005
Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P‐glycoprotein: implications for drug delivery and activity in cancer chemotherapy
VJ Wacher, CY Wu, LZ Benet
Molecular carcinogenesis 13 (3), 129-134, 1995
10921995
Pharmacokinetics: the dynamics of drug absorption, distribution, metabolism, and elimination
LZ Benet, D Kroetz, L Sheiner, J Hardman, L Limbird
Goodman and Gilman’s the pharmacological basis of therapeutics 3, e27, 1996
10041996
Clearance concepts in pharmacokinetics
M Rowland, LZ Benet, GG Graham
Journal of pharmacokinetics and biopharmaceutics 1 (2), 123-136, 1973
9541973
Noncompartmental determination of the steady‐state volume of distribution
LZ Benet, RL Galeazzi
Journal of pharmaceutical sciences 68 (8), 1071-1074, 1979
9111979
Role of intestinal P‐glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine
KS Lown, RR Mayo, AB Leichtman, H Hsiao, DK Turgeon, ...
Clinical pharmacology & therapeutics 62 (3), 248-260, 1997
8791997
BDDCS, the Rule of 5 and drugability
LZ Benet, CM Hosey, O Ursu, TI Oprea
Advanced drug delivery reviews 101, 89-98, 2016
7202016
The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein
Y Zhang, LZ Benet
Clinical pharmacokinetics 40, 159-168, 2001
7002001
BDDCS applied to over 900 drugs
LZ Benet, F Broccatelli, TI Oprea
The AAPS journal 13, 519-547, 2011
6912011
Gender effects in pharmacokinetics and pharmacodynamics
RZ Harris, LZ Benet, JB Schwartz
Drugs 50, 222-239, 1995
6551995
Role of P‐glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics
VJ Wacher, JA Silverman, Y Zhang, LZ Benet
Journal of pharmaceutical sciences 87 (11), 1322-1330, 1998
5971998
Design and optimization of dosage regimens; pharmacokinetic data
LZ Benet
The pharmacological basis of therapeutics 9/e, 1996
571*1996
Acyl glucuronides revisited: is the glucuronidation proces a toxification as well as a detoxification mechanism?
HS Langguth, LZ Benet
Drug metabolism reviews 24 (1), 5-47, 1992
5371992
Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption
JM Custodio, CY Wu, LZ Benet
Advanced drug delivery reviews 60 (6), 717-733, 2008
5232008
The role of transporters in the pharmacokinetics of orally administered drugs
S Shugarts, LZ Benet
Pharmaceutical research 26, 2039-2054, 2009
4932009
Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction
MF Hebert, JP Roberts, T Prueksaritanont, LZ Benet
Clinical Pharmacology & Therapeutics 52 (5), 453-457, 1992
4481992
Differentiation of absorption and first‐pass gut and hepatic metabolism in humans: studies with cyclosporine
CY Wu, LZ Benet, MF Hebert, SK Gupta, M Rowland, DY Gomez, ...
Clinical Pharmacology & Therapeutics 58 (5), 492-497, 1995
4291995
Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4
CL Cummins, W Jacobsen, LZ Benet
Journal of Pharmacology and Experimental Therapeutics 300 (3), 1036-1045, 2002
4192002
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20